Arch Biopartners Inc.

ACHFF

CA03938C1041

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 16:05:05 16/01/2026 GMT			5-day change	1st Jan Change
0.9904 ^USD	+0.99%		+3.71%	+12.11%

01-16	Arch Biopartners Appoints Patrick Vink as Chairman	MT
01-16	Arch Biopartners Inc. Announces Appointment of Patrick Vink as Chairman of the Board and Retirement of Claude Allary from the Board of Directors	CI

Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2024

Published on 01/29/2025 at 03:42 am GMT

S&P Capital IQ

Arch Biopartners Inc.

+0.99%

Arch Biopartners Inc. reported earnings results for the full year ended September 30, 2024. For the full year, the company reported net loss was CAD 3.92 million compared to CAD 3.33 million a year ago. Basic loss per share from continuing operations was CAD 0.062 compared to CAD 0.053 a year ago.

Latest news about Arch Biopartners Inc.

01-16	Arch Biopartners Appoints Patrick Vink as Chairman	MT
01-16	Arch Biopartners Inc. Announces Appointment of Patrick Vink as Chairman of the Board and Retirement of Claude Allary from the Board of Directors	CI
12-16	Arch Biopartners Says Toronto's St Michael's Hospital Cleared to Participate in Phase II Trial Related To Kidney Injury	MT
12-16	Arch Biopartners Inc. Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide	CI
11-19	Arch Biopartners closes non-brokered private placement	RE
11-18	Arch Biopartners Inc. announced that it has received CAD 0.6 million in funding	CI
11-10	Arch Biopartners to Launch $500,000 Non-Brokered Private Placement Offering	MT
11-10	Arch Biopartners Inc. announced that it expects to receive CAD 0.5 million in funding	CI
11-05	Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia	MT
11-05	Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia	CI
20/10/25	Arch Biopartners Inc.(TSXV:ARCH) dropped from S&P/TSX Venture Composite Index	CI
17/09/25	Arch Biopartners Acquires Platform to Develop New Drugs Targeting Chronic Kidney Disease	MT
17/09/25	Arch Biopartners Inc. Acquires Pre-Clinical Platform Developing New Drugs to Treat Chronic Kidney Disease	CI
16/09/25	Arch Biopartners Inc. (OTCPK:ACHF.F) agreed to acquire Lipdro Therapeutics Inc. from Justin Chun for CAD 0.41 million.	CI
30/08/25	Arch Biopartners Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
06/08/25	Arch Biopartners Doses First Patient in Phase II Trial of LSALT Peptide	MT
06/08/25	Arch Biopartners Inc. Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury	CI
22/07/25	Arch Biopartners Starts Patient Recruitment In Phase II Cilastatin Trial	MT
22/07/25	Arch Biopartners Inc. Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury	CI
31/05/25	Arch Biopartners Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025	CI
22/04/25	Arch Biopartners Says Toronto General Hospital Cleared to Join LSAT Peptide Trial	MT
22/04/25	Arch Biopartners Inc. Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)	CI
14/03/25	Arch Biopartners Closes Non-Brokered Private Placement	RE
13/03/25	Arch Biopartners Inc. announced that it has received CAD 0.37325 million in funding	CI
05/03/25	Arch Biopartners to Raise $350,000 in Private Placement	MT

Chart Arch Biopartners Inc.

Duration

Period

ACHFF: Dynamic Chart

Company Profile

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Companyâs lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

Employees

Sector

Pharmaceuticals

Calendar

02-02 - Q4 2025 Earnings Release (Projected)

More about the company